Quest Diagnostics Stock News

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List.

IHF: A Standout Performer With Strong Future Growth Prospects

SECAUCUS, N.J. , March 30, 2022  /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quart

According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.

Quest Diagnostics' (DGX) COVID-19 serological tests, nationwide reach and data analytics capabilities will help assess COVID-19 vulnerability throughout the country.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Novartis Announces FDA Approval Of Prostate Cancer Drug Pluvicto Novartis AG (NYSE: NVS) said the U.S.

According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.

When the markets go through the massive transitions they're seeing right now, it's a great time to add quality healthcare stocks. The post 7 Healthcare Stocks to Buy for the Long Term appeared first o

NEW YORK, March 12, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Quest Diagnostics Incorporated (“Quest” or the “Company”) (NYSE: DGX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Let's see if Quest Diagnostics Incorporated (DGX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Let's see if Quest Diagnostics Incorporated (DGX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Quest Diagnostics (DGX) raises 2022 guidance based on the continued rebound in base business and recent investments expected to accelerate growth.

Quest Diagnostics (DGX) raises 2022 guidance based on the continued rebound in base business and recent investments expected to accelerate growth.

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP ( www.JohnsonFistel.com ) is investigating whether Quest Diagnostics Incorporated ("Quest" or the "Company") (NYSE: DGX ), any of its executive officers, or others violated federal securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. What actions may I take at this time? If you purchased Torrid securities and suffered significant losses on your investment, contact Johnson Fistel, LLP to submit your losses: Contact Lead Securities Analyst Jim Baker at [email protected] or (619) 814-4471 Click [ here ] or paste the following web address into your browser to join the investigation: https://www.cognitoforms.com/JohnsonFistel/QuestDiagnosticsIncorporated2 For more information, visit our website at Full story available on Benzinga.com

Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc. , Quest Diagnostics, Thermo Fisher Scientific Inc. , Pfizer, Bristol-Myers Squibb, Merck & Co. Inc. and Tepnel Pharma Services. Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc. , Quest Diagnostics, Thermo Fisher Scientific Inc. , Pfizer, Bristol-Myers Squibb, Merck & Co. Inc. and Tepnel Pharma Services.